Skip to content

Destiny Pharma

Invested in:
Calculus VCT

Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections.

The Company is developing novel antimicrobial drugs from its “in-house” XF platform and also from recently acquired Biotherapeutic products that harness beneficial components of the human microbiome. We have two exciting late stage clinical assets and a range of earlier research programmes.


Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

The net proceeds of the Fundraising will allow the Company to continue progress towards Phase 3 trials in its two lead, clinical assets, NTCD-M3 and XF-73 Nasal, and finalise regulatory plans, whilst also strengthening the balance sheet as the Company progresses partnering discussions in relation to NTCD-M3.

Latest News

Calculus invests in Destiny Pharma

Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Read more